Post

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

MediLink Therapeutics has announced early data with a HER3 antibody drug conjugate (ADC) that the biotech is codeveloping with BioNTech, …

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

Merck & Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from Phase II and …

AbbVie’s strong immunology portfolio forecast to combat Humira losses

For 20 years, AbbVie’s Humira (adalimumab) has been one of the world’s top-selling products. However, the US drug expiry in …

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Amongst abstracts announced yesterday for the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting was positive data from a …

Zydus Lifesciences concludes subject enrolment in Phase II ALS trial

Zydus Lifesciences has announced the conclusion of subject enrolment in the Phase II clinical trial of Usnoflast (ZYIL1) to treat …